EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma. - Wikidata - awgldk - TriplyDB

EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.

EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.

http://www.wikidata.org/entity/Q34618994

about

Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study.Synergistic Inhibitory Effects of Cetuximab and Cisplatin on Human Colon Cancer Cell Growth via Inhibition of the ERK-Dependent EGF Receptor Signaling Pathway.Epigenetic and genetic alterations-based molecular classification of head and neck cancer.Epidermal growth factor receptor: an important target in esophageal cancer.Gene Methylation Profiling in Sinonasal Adenocarcinoma and Squamous Cell Carcinoma.Ah receptor antagonism represses head and neck tumor cell aggressive phenotype.Gene amplification and protein overexpression of EGFR and ERBB2 in sinonasal squamous cell carcinoma.Immunohistochemical expression of epidermal growth factor receptor (EGFR) in South Asian head and neck squamous cell carcinoma: association with various risk factors and clinico-pathologic and prognostic parameters.

P2860

Q34980673-C9F527E5-0372-4FC2-BE6E-A05BA568BAD7 Q36146089-B56F918E-BC1B-43E7-86F1-D417C336009A Q37999072-9458D785-120B-4C9A-83E4-DC44921422DA Q38121640-64BB81DF-D66D-429C-9474-6621196E48A5 Q38801128-D19BA15E-DCFC-4DAE-8CC9-84B01541CE79 Q39293280-8D353C9C-1B64-4EAA-9716-A83793781006 Q43634452-353FB46B-AE57-412D-8A12-7D6AB9C29E27 Q55471808-15F2B97F-D766-4223-AF5C-AD40BDDEC0E5

P2860

EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.

http://www.wikidata.org/entity/Q34618994

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.

@ast

EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.

@en

EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.

@nl

type

label

EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.

@ast

EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.

@en

EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.

@nl

prefLabel

EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.

@ast

EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.

@en

EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.

@nl

P1433

Q34618994-489CCDF2-B584-4BC2-966C-89FFE1C2034B

P1476

Q34618994-18099472-EA2C-45D7-869F-D67C31967ED0

P2093

Q34618994-8EA3295D-0DFA-472D-BF02-3FBDBF9ACD5C

Q34618994-BF12DDBB-B989-4948-BD91-616190376792

Q34618994-DC7FE8A9-34CC-46BB-92C3-7143A9C62B05

Q34618994-F64BF25A-E75D-45DF-8488-FE96B80E4C6C

P2860

Q34618994-01C27949-9906-48EE-AE38-B5CF5E2C77D6

Q34618994-031081E1-C8BE-4BD9-A254-B25A22DC0EFF

Q34618994-062FE1C3-B3B8-40F9-A721-FC32498A2536

Q34618994-07379460-7B7F-40F2-886E-9F59FFD1B50D

Q34618994-0AA8975E-5174-49D4-B7EE-8033776FF697

Q34618994-0DE02BB7-2D46-4BFF-9C32-29D5B4F9E696

Q34618994-101EF5AC-7777-4EEE-B190-48AABE2E6E93

Q34618994-10FAC7EB-6BF3-4BE5-B3EF-D25CC2BA6A20

Q34618994-12991D54-E34E-4609-9FB9-505FFF5C60F8

Q34618994-15C35B50-3492-4D7C-8E01-613FAC243B44

P304

Q34618994-C4AD75FB-AD59-47C1-A12A-992B54ADFB17

P31

Q34618994-AAF76021-5B02-42EF-8847-2A36B24733E5

P356

Q34618994-16B8A6DB-9311-47A7-9A58-5C6840B9F91E

P407

Q34618994-CB7820A6-3104-420B-BD5D-730531C5E8C7

P433

Q34618994-77E730EF-1562-4BA5-A1DF-AA0325990979

P478

Q34618994-C99AA51D-8B14-4CDA-8E7E-4811506D49E9

P50

Q34618994-CB4964C2-9432-4E6F-85D5-54D31AF1B496

P577

Q34618994-DF858C29-1FE0-44CF-9280-F6857CE412C3

P698

Q34618994-E4CAE9E1-0103-4822-A9C2-25A86536D341

P921

Q34618994-8EAFEF63-1DD9-4E02-82A2-F66ED5EFCB6A

P356

14728211003716442

P1433

Expert Opinion on Emerging Drugs

P1476

EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.

@en

P2093

Anna Karrila

http://www.w3.org/2001/XMLSchema#string

Janne Nordberg

http://www.w3.org/2001/XMLSchema#string

Maria Sundvall

http://www.w3.org/2001/XMLSchema#string

Reidar Grénman

http://www.w3.org/2001/XMLSchema#string

P2860

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.

P304

185-201

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728211003716442

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20415599

http://www.w3.org/2001/XMLSchema#string

P921

head and neck squamous cell carcinoma